



SINGULAIR® (montelukast sodium)

Fact Sheet

SINGULAIR® (montelukast sodium), a member of an important class of asthma medications called leukotriene receptor antagonists, was discovered in Canada at the Merck Frosst Centre for Therapeutic Research located in Kirkland, Quebec.

Indications

- Chronic treatment of asthma, including day- and night-time symptoms and the prevention of exercise-induced bronchoconstriction.

How SINGULAIR® Works

- SINGULAIR® blocks substances in your lungs called leukotrienes that cause narrowing and inflammation of airways.

Proven Effectiveness and Tolerability

- Efficacy and tolerability data for SINGULAIR® 4 mg chewable tablet in two to five year olds were obtained from a double-blind, placebo-controlled clinical study of 689 patients - the largest study ever conducted among asthmatic children aged two to five. A total of 461 patients received SINGULAIR® 4 mg and 228 received placebo over 12-weeks of therapy. Patients in the study had a history of physician-diagnosed asthma with at least three episodes (such as coughing, wheezing and shortness of breath) within the year prior to the study. Findings of the study showed that:
 - SINGULAIR® 4 mg significantly improved the ability of children with asthma as young as two years of age to continue their daily activities;
 - the tolerability profile of SINGULAIR® 4 mg in children aged two to five years was similar to placebo.

Side Effects

- Side effects for SINGULAIR® were similar to those reported for placebo.

Dosage / Availability / Price

- The recommended dosage for SINGULAIR® 4 mg in pediatric patients aged two to five years is one chewable tablet taken once a day in the evening.
- SINGULAIR® 4 mg tablets are cherry-flavoured and packaged in 30-tablet blister packages.
- SINGULAIR® 4 mg will cost approximately \$1.27 per day - depending on the pharmacist dispensing fee which can vary across the country.

®Registered trademark of Merck & Co., Inc. Used under license.

- 30 -

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

Vincent Lamoureux

Manager, Public Affairs
Merck Frosst Canada Ltd
(514) 428-3456

Roch Landriault / Mélanie Hould

NATIONAL *PharmaCom*
(514) 843-2345 / 843-2373